Arcutis Biotherapeutics Inc.
Rating
Updated: Aug 25, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151...
Latest News
4 days ago · zacks.com
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
5 days ago · seekingalpha.com
Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptArcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
25 days ago · zacks.com
Here's Why You Should Add ARQT Stock to Your Portfolio NowArcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
27 days ago · zacks.com
5 Biotech Stocks Worth Adding to Your Portfolio NowNew drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
2 months ago · seekingalpha.com
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call TranscriptArcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript
2 months ago · zacks.com
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass EstimatesArcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.13 per share a year ago.
2 months ago · marketbeat.com
Arcutis Biotherapeutics Q2 Earnings Call HighlightsArcutis Biotherapeutics NASDAQ: ARQT reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical treatments continued to rise across approved dermatology indications.
2 months ago · zacks.com
4 Biotech Stocks Likely to Outpace Q2 Earnings EstimatesMedical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
2 months ago · zacks.com
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseArcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 months ago · zacks.com
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a BetThe mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ARQT